Clinical Trial: Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07721025) titled 'Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy' on June 24.

Brief Summary: The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).

Study Start Date: June 25

Study Type: INTERVENTIONAL

Condition: Friedreich Ataxia Cardiomyopathy, Secondary

Intervention: GENETIC: LX2006

Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

OTHER: Usual Care

Cohort 1: Participants >=16 years of age with FA-CM Participants will receive usual care f...